Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats
Metadatos
Mostrar el registro completo del ítemAutor
Ruiz Malagón, Antonio Jesús; Rodríguez Sánchez, María José; Rodríguez Sojo, María Jesús; Vezza, Teresa; Algieri, Francesca; Rodríguez Cabezas, María Elena; Rodríguez Nogales, Alba; Gálvez Peralta, Julio JuanEditorial
Frontiers
Materia
Serpylli herba T. serpyllum L. Intestine anti inflammatory activity Visceral analgesia IBS rat model
Fecha
2022-09-02Referencia bibliográfica
Ruiz-Malagón AJ... [et al.] (2022), Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats. Front. Pharmacol. 13:967644. doi: [10.3389/fphar.2022.967644]
Patrocinador
Junta de Andalucia AGR6826 CTS 164; Spanish Government SAF 2011-29648; Instituto de Salud Carlos III; European Commission PI19/01058 PI20/01447Resumen
Ethnopharmacological relevance: Serpylli herba extract (SHE), composed of
the aerial parts of wild thyme (Thymus serpyllum L.) (Lamiaceae family), is
traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers,
intestinal parasites and upper respiratory tract infections. Recently, SHE has
generated a great interest for irritable bowel syndrome (IBS) management,
probably due to its intestinal anti-inflammatory properties shown in
experimental colitis and the fact that its active components could preserve
the intestinal barrier integrity, which is altered in patients with IBS.
Aim of study: We aimed to test the effects of a SHE in a rat experimental model
resembling human IBS.
Materials and methods: IBS was provoked by deoxycholic acid (DCA). Rats
were then treated with SHE (100 mg/kg) or gabapentin (70 mg/kg) and different
inflammatory and gut barrier integrity markers were evaluated. Moreover,
several gut hypersensitivity and hyperalgesia determinations were performed.
Results: SHE improved referred pain and visceral hypersensitivity. Additionally, SHE
enhanced immune status by downregulating of the expression of the proinflammatory
mediators Il-1β, Il-6, Ifn-γ, Tlr-4, and the inducible enzyme Cox-2,
thus inducing visceral analgesia, and promoting the restore of the gut barrier
function by upregulating the mucins Muc-2 and Muc-3. These antiinflammatory effects could be related to its action on mast cells since it significantly
inhibited the β-Hexosaminidase production in RBL-2H3 cells. Lastly, SHE also seems
to modulate the serotonin pathway by restoring the altered expression of the 5-HT
receptors Htr-3 and Htr-4.
Conclusion: SHE could be considered a potential new treatment for IBS, since it
ameliorates hypersensitivity, visceral hyperalgesia, and inflammation. These
beneficial effects may be due to the inhibition of mast cells degranulation
and serotonin pathway.